BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Transcelerate Biopharma Inc.

Headquarters: Conshohocken, PA, United States
Year Founded: 2012
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Oct 17, 2022
Management Tracks

Baranowski becomes CEO at Avalyn

Plus new CMO at Ankyra as Kaufman becomes CEO, and updates from Verge, Zentalis, Aviceda and more
BioCentury | Apr 9, 2022
Finance

5AM refuels, with eye toward new set of opportunities

As Levy, Soteropoulos join team, veteran early-stage investor has $750M in new funds to deploy  
BioCentury | Mar 18, 2022
Product Development

What’s holding back biopharma data science, and how to fix it

A survey by BioCentury and Owkin points to standardization as a top challenge, and highlights the debate on data centralization
BioCentury | Oct 27, 2021
Regulation

How Woodcock has changed FDA

In 35 years at FDA, Janet Woodcock has reshaped the way drugs are regulated and developed
BioCentury | Oct 13, 2021
Management Tracks

Stoffels ushered in half a dozen blockbusters for J&J

And nearly as many HIV drugs, plus one of the first COVID-19 vaccines
BioCentury | Mar 19, 2021
Product Development

Pandemic response ushers in new era of biopharma data sharing: Guest Commentary

The COVID R&D Alliance tells the story of a pharma data sharing initiative that could extend beyond COVID-19
BioCentury | Oct 30, 2020
Product Development

TransCelerate looks to sustain momentum of data sharing post-pandemic

TransCelerate adds clinical trial conduct, real world data and pharmacovigilance agreement initiatives to its data sharing platform
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

COVID-19 has lit a path to greater data sharing
BioCentury | Sep 7, 2020
Product Development

Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change 

BioCentury calls on industry to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis
Items per page:
1 - 10 of 47